U.S. markets closed
  • S&P Futures

    3,826.00
    -2.00 (-0.05%)
     
  • Dow Futures

    31,338.00
    -33.00 (-0.11%)
     
  • Nasdaq Futures

    12,774.00
    -57.75 (-0.45%)
     
  • Russell 2000 Futures

    2,183.60
    -16.40 (-0.75%)
     
  • Crude Oil

    63.11
    -0.42 (-0.66%)
     
  • Gold

    1,769.00
    -6.40 (-0.36%)
     
  • Silver

    27.40
    -0.28 (-1.03%)
     
  • EUR/USD

    1.2160
    -0.0027 (-0.22%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.3973
    -0.0040 (-0.29%)
     
  • USD/JPY

    106.1050
    -0.1250 (-0.12%)
     
  • BTC-USD

    47,612.59
    -2,736.33 (-5.43%)
     
  • CMC Crypto 200

    950.81
    -43.85 (-4.41%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,338.85
    -829.42 (-2.75%)
     

WAVE Life Sciences: Q2 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of WAVE Life Sciences (NASDAQ:WVE) moved higher by 1% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 5.74% over the past year to ($1.15), which missed the estimate of ($0.97).

Revenue of $3,027,000 declined by 60.32% year over year, which missed the estimate of $5,650,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

WAVE Life Sciences hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Aug 10, 2020

View more earnings on WVE

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/tp8dtbav

Recent Stock Performance

52-week high: $39.98

Company's 52-week low was at $6.61

Price action over last quarter: down 9.49%

Company Profile

WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.